Clinical Trial Update: Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gecacitinib with a corticosteroid as first-line therapy for grade II-IV acute graft-versus-host disease; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Corticosteroid (corticosteroid)
• Gecacitinib (Gecacitinib)

Snippet

Sponsor: Bin Gu | Conditions: aGVHD | Phase 2 | Status: NOT_YET_RECRUITING